LGD-6972

Research use only, not for human use.

LGD-6972 (RVT 1502) is a novel potent, selective, orally bioavailable glucagon receptor (GCGR) antagonist.

LGD-6972 (RVT 1502) is a novel potent, selective, orally bioavailable glucagon receptor (GCGR) antagonist; binds competitively to GCGR with high affinity and selectivity, suppressing both cAMP and glucose production in vitro; reduces acute glucagon-stimulated hyperglycaemia as well as the hyperglycaemia observed in diabetic mouse models in vivo.Diabetes Phase 2 Clinical.

In vitro, LGD-6972 binds competitively to glucagon receptor (GCGR) with high affinity and selectivity, suppressing both cAMP and glucose production.

In vivo, LGD-6972 reduces acute glucagon-stimulated hyperglycaemia as well as the hyperglycaemia observed in diabetic mouse models. The pharmacological activity of LGD-6972 appears to be mediated primarily by inhibiting glucagon receptor signaling.

LGD6972 | RVT 1502

GPCR/G Protein

Glucagon Receptor

Glucagon Receptor

Metabolic Disease

Diabetes

1207989-09-0

702.9008

C43H46N2O5S

>98% (HPLC)

DMSO: ≥ 31 mg/mL

CC1=CC(=C(C(=C1)C)C2=CC=C(C=C2)NC(=O)C(CC3=CC=C(C=C3)C(=O)NCCS(=O)(=O)O)C4=CC=C(C=C4)C5=CC=C(C=C5)C(C)(C)C)C

Ethanesulfonic acid, 2-[[4-[(2R)-2-[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl]-3-oxo-3-[(2',4',6'-trimethyl[1,1'-biphenyl]-4-yl)amino]propyl]benzoyl]amino]-

(-20℃)

With Ice Pack

≥ 2 years